Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Otsuka Holdings Co ( (JP:4578) ).
Otsuka Holdings Co., Ltd. reported a year-on-year decline in its nonconsolidated financial results for the fiscal year ended December 31, 2025, with operating revenues falling 16.3% to ¥98.8 billion and net profit dropping 15.5% to ¥89.9 billion. Earnings per share also decreased from ¥196.52 to ¥169.52, reflecting weaker single-entity performance despite its broader group operations.
The company attributed the downturn primarily to a reduction in dividends received from its subsidiaries, which pressured operating income and ordinary income by nearly 20% compared with the prior year. The results highlight Otsuka Holdings’ dependence on intra-group dividend flows for its standalone profitability, a factor of interest for shareholders assessing the stability of its nonconsolidated earnings base.
The most recent analyst rating on (JP:4578) stock is a Buy with a Yen12600.00 price target. To see the full list of analyst forecasts on Otsuka Holdings Co stock, see the JP:4578 Stock Forecast page.
More about Otsuka Holdings Co
Otsuka Holdings Co., Ltd. is a Japan-based healthcare company listed on the Prime Market of the Tokyo Stock Exchange under code 4578. Through its group, it focuses on pharmaceuticals, nutraceuticals, and related businesses, deriving a significant portion of its nonconsolidated earnings from dividends received from subsidiaries.
Average Trading Volume: 1,094,194
Technical Sentiment Signal: Buy
Current Market Cap: Yen5200.1B
For a thorough assessment of 4578 stock, go to TipRanks’ Stock Analysis page.